News and Trends 18 Jul 2017 German Biotech Strikes License Deal with Japanese Dermatology Firm 4SC has granted an exclusive worldwide license to the Japanese dermatology firm Maruho on a class of compounds against the Kv1.3 ion channel. Under the agreement, 4SC could receive up to €105M in upfront and milestone payments plus royalties on future sales. The deal is part of the German company’s strategy to out license non-core […] July 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 18 Jul 2017 Is DNA the Future? The Best Biotech Talks of the Year We’ve compiled our favorite talks of the year by some of the best leaders in the field about how biotech will change our lives in coming years. Biotech is rapidly advancing thanks to the huge improvements the technology to both read and write DNA has experienced in the past years. While devices become smaller and […] July 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 17 Jul 2017 Israeli Biotech Partners with German Chem Giant to Develop Non-GMO Herbicide Resistance Kaiima and BASF have partnered to develop crops with new herbicide resistance traits using non-GMO genetic engineering technology. Kaiima Bio Agritech works on boosting crop performance by using the plant’s own DNA, without the need of introducing external genes. In order to leverage this technology, the company has partnered with the giant chemical company BASF to discover […] July 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 15 Jul 2017 Speculative Biology in Art: How will Life Look like in the Future? The first solo exhibition of Turkish artist Pinar Yoldas imagines a future where biology is shaped by climate change and plastic pollution. Last week in Amsterdam opened Carboniferous, a solo bioart exhibition by Pinar Yoldas focusing on speculative biology. This concept revolves around imagining how life will evolve according to predictions of how the planet’s future ecosystems […] July 15, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2017 British Researchers “Calm Down” Macrophages to treat Inflammation Imperial College London and Ergon Pharmaceuticals have a new enzyme target to treat inflammatory disease by reducing the activity of macrophages. Researchers at Imperial College London have developed a method to reprogram macrophages and reduce their inflammatory activity. The approach, published in Nature Communications, proved to reduce by more than half inflammation in the joints […] July 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2017 Update: France and the Netherlands deem Oxitec’s GM Mosquitoes Safe for Release Update (12/07/2017): France’s High Council for Biotechnology (HCB) has also backed the use, with caution, of genetically modified mosquitoes in France. Oxitec expects the report published by the HCB will help shape the policy to regulate the genetically engineered insects in France and eventually allow testing the technology in the French Caribbean. Originally published on 07/07/2017 A […] July 12, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jul 2017 French Biotech and Canadian University to treat Rare Disease with Red Blood Cells Erytech Pharma has entered a partnership with Queen’s University to treat the rare disease arginase-1 deficiency using engineered red blood cells. Erytech, based in Lyon, is known for its unique technology for drug delivery. Its most advanced program, in Phase IIb for metastatic pancreatic cancer, employs red blood cells engineered to produce the enzyme L-asparaginase, which depletes […] July 12, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2017 Finnish AI Biotech Raises €14M to Open the Bottleneck of Next-Generation Sequencing Blueprint Genetics has raised €14M to boost its genetic diagnostics platform, using artificial intelligence to interpret next-generation sequencing data. Based in Helsinki, Finland, Blueprint Genetics is a startup that addresses the main bottleneck of genetic testing through next-generation sequencing (NGS), the interpretation of massive volumes of data, with the aid of artificial intelligence (AI). Its […] July 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 11 Jul 2017 Enterome and Nestle Launch a New Microbiome Diagnostics Company Microbiome Diagnostics Partners will develop diagnostics tests with Enterome’s microbiome platform IP and a €20M investment from Nestlé. Nestlé Health Science and Enterome have created Microbiome Diagnostics Partners (MDP) as a joint venture split 50% between both parties. Nestlé has invested €20M for its stake in the new company as well as the exclusive option to commercialize […] July 11, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jul 2017 Swiss Biotech Starts Phase II Trial to Treat Motor Symptoms of Parkinson’s Prexton Therapeutics has launched a Phase II trial to test whether its drug foliglurax can treat the motor complications of standard levodopa therapy. The Phase II trial will enroll 165 patients across the UK, Germany, France, Austria, Spain and Italy to monitor the effects of Prexton’s foliglurax. The company is looking for patients that have been treated […] July 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jul 2017 Danish Diabetes Biotech Shoots for a €75M IPO in the US Nasdaq Zealand Pharma, known for its partnership with Sanofi to boost the insulin blockbuster Lantus, is aiming high in an IPO on the US Nasdaq. Zealand Pharma has announced it has already filed for an IPO at the Nasdaq Global Select Market, an exclusive listing for large cap companies. Currently listed on the Nasdaq Copenhagen, Zealand Pharma […] July 10, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 10 Jul 2017 Sanofi and US Partner Launch Phase III Trial in Hemophilia with RNAi Alnylam and its partner Sanofi are starting a Phase III program to enter its RNAi drug fitusiran in the competitive hemophilia market. Sanofi and its partner Alnylam have announced the start of a Phase III program that seeks to recruit 250 patients to test its RNAi drug fitusiran in patients with both hemophilia A and […] July 10, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email